Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
SWOG S1827/MAVERICK: phase III PCI 25 Gy/10 fx + MRI vs MRI surveillance alone in LS or ES SCLC; design only, no CFFS or OS results in source.
Thoracic carried the day's only study. MAVERICK tests whether MRI surveillance can replace PCI in LS or ES SCLC, with cognitive failure-free survival as 1° EP. Source shows design and eligibility only, no CFFS or OS results. The RT decision at stake is PCI omission; discretionary HA-PCI and salvage RT choices will complicate the cognitive read.
read the full digest →Studies · 129
- SWOG S1827/MAVERICKRandomized phase III, LS or ES SCLC: PCI 25 Gy/10 fx + MRI vs MRI surveillance alone; no CFFS or OS results in source tweets.
- TORPEdO18% vs 7% 12-mo G-tube dependence/≥20% weight loss (p=0.079), UW-QoL 78.3 vs 77.1 (p=0.56): IMPT not superior to IMRT, locally advanced oropharyngeal SCC.
- PROTEUS5-yr BCR-FS 44%, MFS 71%, CSS 92% at 60-mo median f/u in a real-world high-risk prostate cancer benchmark cohort.
- MARCAP ConsortiumIPD meta-analysis, 10,853 pts: ADT added to RT improved MFS HR 0.83 and OS HR 0.86; dose escalation improved bRFS only.
- STAR-TREC12-mo TME-free survival 78.5% vs 60.6% (HR 1.90) favouring LCCRT over SCRT for organ preservation in mrT1-T3bN0 rectal cancer ≤40 mm.
- Focal Ablation vs IMRT Toxicity (SEER-Medicare)GI toxicity favored focal therapy at 24mo (11.0% vs 21.5%, OR 0.45) but GU toxicity favored IMRT (41.7% vs 29.3%, OR 1.69).
- NRG-GU0053yr DFS 88.6% SBRT vs 92.1% MH-IMRT, superiority rejected (adjusted HR 1.40, 0.91-2.13); bowel and GU toxicity favored SBRT.
- Testosterone recovery post-ADT discontinuation (podcast review)Review of two datasets: 25% of real-world pts recovered T within 12mo; 54% relugolix vs 3% leuprolide at 90d in HERO.
- Moderately hypofractionated partial breast reirradiation40Gy/15fx PBI re-RT after second lumpectomy: 3yr LR-FS, DR-FS and OS all 86%, no grade 3+ late events (N=11).
- NSABP B-35 margin-width analysis10yr IBTR 5.6% vs 4.0% at 1mm cutoff (abs diff 1.6%), 5.3% vs 3.8% at 2mm (abs diff 1.5%).
- Cardiac Risk After Heart-Sparing Breast RadiotherapyMax LAD ≥12 Gy EQD2: sHR 1.81 (1.04-3.16) for cardiac events; mean heart dose ≥2 Gy null (P=.99), 2223 left-sided pts.
- Organs at Risk Radiation Dose Constraints: 2025 UpdateSFRO 2025 OAR dose-constraint update: normofractionated, moderate hypofractionated and ablative tables across skull base, H&N, lung, breast, oesophagus, liver.